Comparative Pharmacology
Head-to-head clinical analysis: CEFUROXIME SODIUM IN PLASTIC CONTAINER versus VELOSEF 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFUROXIME SODIUM IN PLASTIC CONTAINER versus VELOSEF 250.
CEFUROXIME SODIUM IN PLASTIC CONTAINER vs VELOSEF '250'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime is a beta-lactam cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has bactericidal activity against susceptible organisms.
Bactericidal antibiotic that inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically inhibiting transpeptidase activity, leading to cell lysis.
1.5 g IV every 8 hours for moderate to severe infections; may be increased to 3 g IV every 8 hours for severe or life-threatening infections.
250 mg orally every 6 hours for adults with normal renal function.
None Documented
None Documented
Terminal elimination half-life: 1.2-1.9 hours. Prolonged in renal impairment (up to 15-20 hours with CrCl <20 mL/min).
1.2-1.5 hours in normal renal function; prolonged in renal impairment (up to 10-20 hours in ESRD)
Renal excretion: 80-90% unchanged by glomerular filtration and tubular secretion. Biliary/fecal: <10%.
Primarily renal (80-90% unchanged by glomerular filtration and tubular secretion); remainder biliary/fecal (<10%)
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic